ENDV (Endonovo Therapeutics) Short-Term Debt: $6.90 Mil (As of Jun. 2025)


What is Endonovo Therapeutics Short-Term Debt?

Endonovo Therapeutics ENDV Short-Term Debt is $6.90 Mil as of Jun. 2025.

Endonovo Therapeutics's Short-Term Debt for the quarter that ended in Jun. 2025 was $6.90 Mil.

Endonovo Therapeutics's quarterly Short-Term Debt stayed the same from Dec. 2024 ($6.87 Mil) to Mar. 2025 ($6.87 Mil) but then increased from Mar. 2025 ($6.87 Mil) to Jun. 2025 ($6.90 Mil).

Endonovo Therapeutics's annual Short-Term Debt declined from Dec. 2022 ($7.15 Mil) to Dec. 2023 ($7.07 Mil) and declined from Dec. 2023 ($7.07 Mil) to Dec. 2024 ($6.87 Mil).

Endonovo Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Endonovo Therapeutics Short-Term Debt Related Terms

Endonovo Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics Short-Term Debt Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.63 7.18 7.15 7.07 6.87

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.02 7.02 6.87 6.87 6.90
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $6.90 Mil mean?
Endonovo Therapeutics (ENDV) has a Short-Term Debt of $6.90 Mil as of Jun. 2025.
Is Endonovo Therapeutics' Short-Term Debt too high?
Endonovo Therapeutics' current Short-Term Debt is $6.90 Mil.
How does Endonovo Therapeutics' Short-Term Debt compare to RGBP and SIGY?
Endonovo Therapeutics' Short-Term Debt of $6.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Endonovo Therapeutics's current Short-Term Debt is $6.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Short-Term Debt of $6.90 Mil. The current Short-Term Debt is $6.90 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Short-Term Debt is $6.90 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.